OnCo

CREBBP (CREB-binding protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Bladder & urothelial cancer, Leukaemia and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-BMAL1 and CLOCK-BMAL1 heterodimers. Location: Cytoplasm; Nucleus (UniProt). Locus 16p13.3 (HGNC).

Where it is found
  • Non-Hodgkin lymphoma: Open Targets association 0.74 with non-Hodgkin lymphoma (MONDO_0018908); CIViC evidence names this disease
  • Bladder & urothelial cancer: Open Targets association 0.66 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 7 cohorts (BLADDER, BLCA, UTUC)
  • Leukaemia: Open Targets association 0.65 with leukaemia (MONDO_0005059)
  • Neuroendocrine tumours: Open Targets association 0.60 with neuroendocrine neoplasm (MONDO_0019496); IntOGen driver in 1 cohort (NETNOS)
  • Oesophageal cancer: Open Targets association 0.54 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA)
  • Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)
Class: transcription · Gene: CREBBP · Facts checked 2026-09-23 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"CREBBP" OR ABSTRACT:"CREBBP" OR TITLE:"CREB binding lysine acetyltransferase" OR ABSTRACT:"CREB binding lysine acetyltransferase" OR TITLE:"CREB-binding protein" OR ABSTRACT:"CREB-binding protein" OR TITLE:"KAT3A" OR ABSTRACT:"KAT3A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CREBBP, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/crebbp.json. Licence CC BY-NC 4.0.